January 06, 2007 at 1:02 pm by Tom Lydon
Biotech focused exchange traded funds (ETFs) could soon be effected by the upcoming success of Monsanto (MON), a crop biotech company. Carey Gillam of Reuters reports the company’s research and development is accelerating at a record pace and 2007 will be the biggest year yet for screening and testing genes.
Other biotech companies have been performing well and have helped push up the biotech ETFs. Amgen (AMGN) and Genentech (DNA) are top holders in the two ETFs listed below. These companies have encouraging products in the pipeline and product sales have been on the rise.
Tags: Biotechnology
Subscribe to Our RSS Feed
